Loading...
XNAS
SYBX
Market cap8mUSD
Jul 10, Last price  
0.71USD
1D
1.89%
1Q
14.30%
Jan 2017
-99.62%
IPO
-99.90%
Name

Synlogic Inc

Chart & Performance

D1W1MN
XNAS:SYBX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
38.81%
Rev. gr., 5y
-67.55%
Revenues
0k
-100.00%
00000444,0002,444,0002,520,0002,224,000545,0001,754,0001,180,0003,371,0008,0000
Net income
-1m
L-95.70%
-2,883,000-3,658,000-6,436,000-15,834,000-24,983,000-26,268,000-40,377,000-48,435,000-51,373,000-59,173,000-60,561,000-66,147,000-57,282,000-23,359,000-1,005,000
CFO
-4m
L-86.23%
-4,520,000-6,496,000-13,970,000-21,135,000-24,805,000-31,055,000-42,470,000-75,468,000-39,553,000-52,198,000-56,888,000-51,614,000-31,658,000-4,359,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
URL
https://www.synlogictx.com/
IPO date
Sep 30, 2015
Employees
72
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT